GlycoMimetics Inc (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases, announced on Tuesday that it has entered into an acquisition agreement with privately held biotechnology company Crescent Biopharma Inc.
The combined company will focus on advancing Crescent's pipeline of oncology therapeutics, including the tetravalent PD-1 x VEGF bispecific antibody CR-001 which is expected to have preliminary proof of concept data in the second half of 2026. Additionally, Crescent is developing two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003.
A syndicate of investors has committed USD200m to fund operations through 2027.
Pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company, with the pre-acquisition Crescent stockholders owning approximately 96.9%.
Insilico Medicine reports positive results from Phase I ISM5411 studies in Australia and China
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
argenx receives Japanese approval for VYVDURA in chronic inflammatory demyelinating polyneuropathy
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Vanda Pharmaceuticals receives Orphan Drug Designation from FDA for VGT-1849A
Hansa Biopharma reports positive Phase 2 imlifidase results
Gilead Sciences secures positive CHMP opinion for seladelpar in PBC treatment
GSK's Submission for Nucala (mepolizumab) in COPD accepted by US FDA
Evommune presents positive data from EVO756 first-in-human proof-of-concept trial
Rigel Pharmaceuticals' R289 granted US FDA Fast Track designation
Revelation Biosciences secures FDA acceptance for Gemini IND, Phase 1b CKD study set for 2025
Formosa Pharmaceuticals licenses eye drops for Switzerland and Liechtenstein